Dr. Josep Comín, co-author of two publications in Nature Medicine and JACC on a new drug against heart failure

  • The international group of scientists who have discovered the benefits of dapagliflozin in the treatment of heart failure, including Dr. Josep Comín, head of the IDIBELL BIO-Heart Research Group on Cardiovascular Diseases and the Cardiology Service of the Hospital de Bellvitge, has published new disaggregated results of this research in the leading scientific journals Nature Medicine and the Journal of the American College of Cardiology (JACC).
NO013 - J Comin_Deliver study - Imatge noti

These two new publications present the results obtained in specific subgroups of patients from the DELIVER trial. Whose global conclusions were presented worldwide last August at the Congress of the European Society of Cardiology in Barcelona and in The New England Journal of Medicine.

In Nature Medicine, the group published this December the article “Dapagliflozin in heart failure-re with improved ejection fraction: in prespecified analysis of the DELIVER trial”. In this publication, a specific analysis of the effects of dapagliflozin is performed in patients in whom the ejection fraction (the percentage of blood that the left ventricle pumps with each contraction) has improved due to the effects of therapeutic action. The results conclude that, in this group of patients, the drug reduces deaths and worsening episodes of the disease.

For its part, the publication in the Journal of the American College of Cardiology titled “Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Recuded Ejection Fraction” reflects the effects of the drug in patients in whom the ejection fraction has been maintained or slightly reduced. According to the conclusions, the clinical benefits of dapagliflozin in this group of patients are especially prominent in those who present a greater deterioration of the initial symptoms.

The general conclusions of the DELIVER trial will imply a change in the recommendations for the treatment of heart failure, to reinforce the earlier use of dapagliflozin in patients. The Bellvitge Hospital and the IDIBELL BIO-Heart Group, under the direction of Dr. Comín, have coordinated the more than 300 patients from all over the state who have participated in the study, out of a total of more than 6,200 throughout the world.



The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).

Scroll to Top